The prognostic significance of DNMT3A mutation and CD7 expression in AML is still inconclusive, and there are currently no studies exploring the clinical significance of DNMT3A mutation combined with CD7 expression in AML patients. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.